Cerevel Therapeutics (NASDAQ:CERE – Free Report) had its price target decreased by Mizuho from $29.00 to $25.00 in a research report released on Monday, MarketBeat reports. Mizuho currently has a neutral rating on the biotechnology company’s stock. A number of other research analysts have also weighed in on the stock. Bank of America lowered shares […]
Cerevel Therapeutics (NASDAQ:CERE) Sets New 12-Month Low Following Analyst Downgrade theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Cerevel Therapeutics (NASDAQ:CERE) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Cerevel Therapeutics (NASDAQ:CERE – Get Free Report) issued its earnings results on Wednesday. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.02, Briefing.com reports. During the same quarter in the previous year, the firm earned ($0.61) earnings per share. Cerevel Therapeutics Trading Down 9.9 […]
Cerevel Therapeutics (NASDAQ:CERE – Get Free Report) will release its earnings data before the market opens on Wednesday, August 2nd. Analysts expect Cerevel Therapeutics to post earnings of ($0.67) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link. Cerevel Therapeutics (NASDAQ:CERE – Get […]